Literature DB >> 12558324

Testing a symptom-based surveillance system at high-profile gatherings as a preparatory measure for bioterrorism.

K Osaka1, H Takahashi, T Ohyama.   

Abstract

We tested symptom-based surveillance during the G8 conference in 2000 as a means of detecting outbreaks, including bio-terrorism attacks, promptly. Five categories of symptoms (skin and haemorrhagic, respiratory, gastrointestinal, neurological and unexplained) were adopted for the case definition of the surveillance. The surveillance began I week before the conference, and continued until 1 week after the conference ended. We could not detect any outbreaks during this surveillance. Compared to the existing diagnosis-based surveillance system, symptom-based surveillance has the advantages of timeliness and simplicity. However, poor specificity and difficulties in determining epidemic threshold were important limitations of this system. To increase the specificity of surveillance, it is essential to incorporate rapid laboratory diagnoses into the system.

Entities:  

Mesh:

Year:  2002        PMID: 12558324      PMCID: PMC2869903          DOI: 10.1017/s0950268802007689

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  3 in total

1.  Can syndromic surveillance data detect local outbreaks of communicable disease? A model using a historical cryptosporidiosis outbreak.

Authors:  D L Cooper; N Q Verlander; G E Smith; A Charlett; E Gerard; L Willocks; S O'Brien
Journal:  Epidemiol Infect       Date:  2006-02       Impact factor: 2.451

Review 2.  Review of syndromic surveillance: implications for waterborne disease detection.

Authors:  Magdalena Berger; Rita Shiau; June M Weintraub
Journal:  J Epidemiol Community Health       Date:  2006-06       Impact factor: 3.710

3.  A multi-data source surveillance system to detect a bioterrorism attack during the G8 Summit in Scotland.

Authors:  N Meyer; J McMenamin; C Robertson; M Donaghy; G Allardice; D Cooper
Journal:  Epidemiol Infect       Date:  2007-08-03       Impact factor: 2.451

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.